BPMC - Blueprint Medicines Corporation
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
BPMC price evolution
BPMC
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $65.39 | $123.96 | $81.52 | |
| Short term investments | $708.83 | $534.58 | $639.36 | |
| Net receivables | $65.81 | $85.06 | $60.05 | $43.18 |
| Inventory | $12.53 | $14.79 | $30.94 | $21.22 |
| Total current assets | $854.85 | $903.54 | $776.6 | $808.39 |
| Long term investments | $132.66 | $115.49 | $84.32 | |
| Property, plant & equipment | $104.27 | $109.05 | $113.17 | $115.65 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $300.02 | $261.87 | $240.86 | |
| Total investments | $841.49 | $650.07 | $723.67 | |
| Total assets | $1199.65 | $1203.56 | $1038.47 | $1049.25 |
| Current liabilities | ||||
| Accounts payable | $4.72 | $4.86 | $4.93 | $4.71 |
| Deferred revenue | $11.79 | $11.89 | $5.6 | |
| Short long term debt | $60.92 | $42.42 | $42.21 | |
| Total current liabilities | $257.66 | $243.8 | $206.6 | $214.92 |
| Long term debt | $341.54 | $413.9 | $287.69 | $290.29 |
| Total noncurrent liabilities | $639.52 | $521.18 | $703.72 | |
| Total debt | $474.82 | $330.11 | $332.5 | |
| Total liabilities | $886.5 | $883.32 | $727.79 | $918.64 |
| Shareholders' equity | ||||
| Retained earnings | -$2357.08 | -$2300.8 | -$2250.81 | -$2339.94 |
| Other shareholder equity | -$1.07 | -$3.89 | -$3.85 | -$3.5 |
| Total shareholder equity | $320.24 | $310.69 | $130.61 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $81.52 | $124.9 | $215.12 | $689.8 |
| Short term investments | $639.36 | $825.28 | $267.17 | $187.21 |
| Net receivables | $43.18 | $36.94 | $37.03 | $25.31 |
| Inventory | $21.22 | $29.7 | $21.82 | $8.58 |
| Total current assets | $808.39 | $1046.65 | $554.02 | $927.76 |
| Long term investments | $84.32 | $161.27 | $557.53 | $677.87 |
| Property, plant & equipment | $115.65 | $115.2 | $120.86 | $101.67 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $240.86 | $303.25 | $698.2 | $790.63 |
| Total investments | $723.67 | $986.55 | $824.7 | $865.09 |
| Total assets | $1049.25 | $1349.9 | $1252.22 | $1718.39 |
| Current liabilities | ||||
| Accounts payable | $4.71 | $2.73 | $8.33 | $4.37 |
| Deferred revenue | $5.6 | $18.29 | $36.58 | $41.16 |
| Short long term debt | $42.21 | $27.43 | $8.09 | $7.93 |
| Total current liabilities | $214.92 | $183.23 | $149.76 | $130.8 |
| Long term debt | $290.29 | $122.23 | $103.31 | $81.67 |
| Total noncurrent liabilities | $703.72 | $651.99 | $131.72 | $117.5 |
| Total debt | $332.5 | $242.45 | $111.41 | $89.6 |
| Total liabilities | $918.64 | $835.23 | $281.49 | $248.31 |
| Shareholders' equity | ||||
| Retained earnings | -$2339.94 | -$1832.96 | -$1275.44 | -$631.36 |
| Other shareholder equity | -$3.5 | -$10.44 | -$4.13 | -$5.21 |
| Total shareholder equity | $130.61 | $514.68 | $970.74 | $1470.09 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $128.18 | $138.16 | $96.12 | $71.96 |
| Cost of revenue | $7.59 | $3.19 | $0.21 | |
| Gross Profit | $126.25 | $130.56 | $92.92 | $71.74 |
| Operating activities | ||||
| Research & development | $84.27 | $88.19 | $97.54 | |
| Selling, general & administrative | $89.34 | $83.56 | $79.31 | |
| Total operating expenses | $175.23 | $173.61 | $171.75 | $176.85 |
| Operating income | -$43.05 | -$78.82 | -$105.11 | |
| Income from continuing operations | ||||
| EBIT | -$43.03 | $95.21 | -$105.69 | |
| Income tax expense | $0.27 | $0.1 | $0.18 | $0.06 |
| Interest expense | -$7.62 | $6.86 | $5.89 | $5.17 |
| Net income | ||||
| Net income | -$56.28 | -$49.99 | $89.14 | -$110.92 |
| Income (for common shares) | -$49.99 | $89.14 | -$110.92 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $249.38 | $204.04 | $180.08 | $793.74 |
| Cost of revenue | $12.8 | $26.76 | $25.73 | $0.42 |
| Gross Profit | $236.58 | $177.28 | $154.34 | $793.31 |
| Operating activities | ||||
| Research & development | $427.72 | $477.42 | $601.03 | $326.86 |
| Selling, general & administrative | $295.14 | $237.37 | $195.29 | $157.74 |
| Total operating expenses | $722.86 | $714.79 | $796.33 | $484.6 |
| Operating income | -$486.28 | -$537.52 | -$641.98 | $308.71 |
| Income from continuing operations | ||||
| EBIT | -$487.22 | -$535.51 | -$643.47 | $308.34 |
| Income tax expense | $0.97 | $5.24 | $3 | $1.06 |
| Interest expense | $18.79 | $16.77 | -$2.39 | -$6.6 |
| Net income | ||||
| Net income | -$506.98 | -$557.52 | -$644.09 | $313.88 |
| Income (for common shares) | -$506.98 | -$557.52 | -$644.09 | $313.88 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$49.99 | $89.14 | -$110.92 | |
| Operating activities | ||||
| Depreciation | $6.07 | $7.21 | $3.88 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $28.02 | $24.23 | $22.59 | |
| Total cash flows from operations | -$48.07 | -$101.51 | -$78.93 | |
| Investing activities | ||||
| Capital expenditures | -$2.57 | -$1.1 | -$4.67 | |
| Investments | -$185.72 | $78.23 | $83.44 | |
| Total cash flows from investing | -$81.21 | -$188.29 | $77.13 | $78.77 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $31.21 | $67.33 | $15.61 | |
| Net borrowings | $146.8 | -$0.37 | -$0.04 | |
| Total cash flows from financing | $263.35 | $178.01 | $66.96 | $15.53 |
| Effect of exchange rate | $0.41 | -$0.03 | -$0.14 | $0.49 |
| Change in cash and equivalents | $19.33 | -$58.35 | $42.58 | $15.37 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$506.98 | -$557.52 | -$644.09 | $313.88 |
| Operating activities | ||||
| Depreciation | $20.77 | $20.1 | $12.79 | $12.35 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $92.67 | $98.97 | $91.63 | $75.53 |
| Total cash flows from operations | -$436.85 | -$502.28 | -$298.65 | $387.04 |
| Investing activities | ||||
| Capital expenditures | -$16.06 | -$8.92 | -$3.09 | -$3.16 |
| Investments | $290.1 | -$140.33 | $35.38 | -$431.09 |
| Total cash flows from investing | $274.04 | -$149.54 | -$225.86 | -$434.25 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $21.34 | $8.2 | $50.72 | $617.76 |
| Net borrowings | $97.93 | $137.79 | ||
| Total cash flows from financing | $119.22 | $561.81 | $50.72 | $617.76 |
| Effect of exchange rate | $0.2 | -$0.21 | -$0.89 | -$0.34 |
| Change in cash and equivalents | -$43.58 | -$90.01 | -$473.8 | $570.54 |
News
Fundamentals
| Market cap | $5.13B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 63.45M |
| Revenue | $434.41M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$128.05M |
| Revenue Q/Q | 126.61% |
| Revenue Y/Y | 100.93% |
| P/E ratio | -40.06 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 11.81 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.02 |
|---|---|
| ROA | -11.41% |
| ROE | N/A |
| Debt/Equity | 7.03 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.32 |
| Quick ratio | 3.27 |